Author:
Di Cosimo S.,Alimonti A.,Ferretti G.,Sperduti I.,Carlini P.,Papaldo P.,Fabi A.,Gelibter A.,Ciccarese M.,Giannarelli D.,Mandalà M.,Milella M.,Ruggeri E.M.,Cognetti F.
Reference30 articles.
1. Side effects of adjuvant treatment of breast cancer;Shapiro;N Engl J Med,2001
2. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
3. Menstrual disruption in premenopausal breast cancer patients receiving CMF (IV) vs AC adjuvant chemotherapy;Bryce,1998
4. Phase III trial comparing TAC (docetaxel, oxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: interim analysis of the BCIRG 001 study;Nabholtz,2002
5. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients;Goldhirsch;Ann Oncol,1990
Cited by
53 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献